Table of contents
- Clinical trials overview
- Who was studied
- What the study tested
- Study endpoints and safety checks
- Trial status and size
Clinical trials overview
The available trial data show one interventional study of Ab-729 in people with chronic HBV infection.[1] The study was titled an open-label study of imdusiran (AB-729) with intermittent dosing of durvalumab in subjects with chronic HBV infection.[1]
Ab-729 is described in the trial record as imdusiran (AB-729), and the study also used durvalumab, listed as IMFINZI, as part of the treatment plan.[1] The brief summary says the trial aimed to evaluate the safety and tolerability of imdusiran and durvalumab in NA-suppressed chronic HBV subjects.[1]
Who was studied
The target population was people with chronic HBV infection, meaning long-lasting hepatitis B infection.[1] The study specifically included NA-suppressed subjects, which means their hepatitis B virus was already being controlled with nucleic acid analog treatment.[1]
This focus matters because the trial was not designed for all people with hepatitis B, but for a more specific group whose virus was already suppressed.[1]
What the study tested
The trial tested Ab-729 together with intermittent dosing of durvalumab.[1] Intermittent dosing means the medicine is given at set times rather than continuously.[1]
The study used an open-label design, which means both the researchers and the participants knew what treatment was being given.[1] This type of design is often used when the main goal is to watch safety and tolerability closely.[1]
Study endpoints and safety checks
The primary outcome measures focused on safety.[1] These included the frequency and severity of treatment-emergent adverse events (TEAEs), immune-related adverse events (irAEs), and treatment stops because of these events.[1]
The study also measured laboratory abnormalities by cohort, which means researchers checked whether blood or other lab tests moved outside the normal range in each study group.[1] In addition, the trial tracked vital signs, physical exam findings, and electrocardiogram (ECG) abnormalities to watch for possible safety concerns.[1]
Trial status and size
The study was a Phase 2 trial, which is a mid-stage study that usually looks more closely at safety and early treatment effects.[1] The trial status was completed, and the enrollment was 30 participants.[1]
Because only one trial is listed in the source data, the current clinical picture for Ab-729 here is limited to this completed Phase 2 study in chronic HBV infection.[1]
